[go: up one dir, main page]

AR064543A1 - Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales - Google Patents

Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales

Info

Publication number
AR064543A1
AR064543A1 ARP070105911A ARP070105911A AR064543A1 AR 064543 A1 AR064543 A1 AR 064543A1 AR P070105911 A ARP070105911 A AR P070105911A AR P070105911 A ARP070105911 A AR P070105911A AR 064543 A1 AR064543 A1 AR 064543A1
Authority
AR
Argentina
Prior art keywords
treatment
agents
intestinal disorders
mononitrate derivatives
dianhydrohexite mononitrate
Prior art date
Application number
ARP070105911A
Other languages
English (en)
Inventor
Mancini Marisabel Mourelle
Moliner Jose Repolles
Coy Francisco Pubill
Original Assignee
Lacer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38043051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR064543(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lacer Sa filed Critical Lacer Sa
Publication of AR064543A1 publication Critical patent/AR064543A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente se refiere al uso de un compuesto de formula (1) o un tautomero, una sal farmacéuticamente aceptable, un profármaco o un solvato del mismo, como ingrediente o ingredientes activos en la fabricacion de una composicion farmacéutica para la prevencion y/o tratamiento de un trastorno intestinal.
ARP070105911A 2006-12-28 2007-12-27 Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales AR064543A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06380338A EP1941876A1 (en) 2006-12-28 2006-12-28 Isosorbide mononitrate derivatives for the treatment of Inflammation and ocular hypertension

Publications (1)

Publication Number Publication Date
AR064543A1 true AR064543A1 (es) 2009-04-08

Family

ID=38043051

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105911A AR064543A1 (es) 2006-12-28 2007-12-27 Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales

Country Status (21)

Country Link
US (1) US20080161389A1 (es)
EP (3) EP1941876A1 (es)
JP (2) JP2010514734A (es)
KR (2) KR20100100584A (es)
CN (2) CN101600426B (es)
AR (1) AR064543A1 (es)
AT (2) ATE484279T1 (es)
AU (2) AU2007341218B2 (es)
BR (2) BRPI0720664A2 (es)
CA (2) CA2674144A1 (es)
CL (2) CL2007003836A1 (es)
DE (2) DE602007007523D1 (es)
ES (3) ES2324130B1 (es)
IL (2) IL198912A0 (es)
MX (2) MX2009007038A (es)
NO (2) NO20092763L (es)
PL (2) PL2114398T3 (es)
RU (2) RU2009128968A (es)
UY (1) UY30847A1 (es)
WO (2) WO2008080939A1 (es)
ZA (2) ZA200903567B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2149576A1 (en) * 2008-07-22 2010-02-03 Lacer, S.A. Isosorbide Nitrates having vasodilating activity
EP2149577B1 (en) * 2008-07-22 2011-04-27 Lacer, S.A. New stereospecific method for the preparation of dioxa-bicyclooctane compounds
EP2177216A1 (en) * 2008-10-13 2010-04-21 Lacer, S.A. Use of dianhydrohexite mononitrate derivatives as healing agents
WO2010055138A1 (en) * 2008-11-14 2010-05-20 Lacer, S.A. New stereospecific method for the preparation of dioxa-bicyclooctane compounds
EP2199294A1 (en) * 2008-12-19 2010-06-23 Lacer, S.A. New stereospecific method for the preparation of dioxa bicyclooctane nitrate compounds
WO2011079273A2 (en) * 2009-12-23 2011-06-30 Arca Biopharma, Inc. Methods and compositions for cardiovascular diseases and conditions
BR112015021072A2 (pt) * 2013-03-05 2017-07-18 Archer Daniels Midland Co processo de preparação de um monotriflato de isohexídeo, composto químico, processo para fabricação de um composto derivado de um monotriflato de isohexídeo, e, composto derivado
WO2018224419A1 (en) 2017-06-06 2018-12-13 Nicox S.A. Nitric oxide donating isomannide derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2739689C2 (de) * 1977-09-02 1986-10-16 Euratom Thermische Wärmepumpe
JPS60149521A (ja) * 1984-01-18 1985-08-07 Eisai Co Ltd 高眼圧・緑内障治療・予防用点眼剤
US5573758A (en) * 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
US5925342A (en) * 1996-11-13 1999-07-20 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
GB9720797D0 (en) * 1997-09-30 1997-12-03 Rhodes John Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome
ES2142773B1 (es) * 1998-10-07 2001-01-01 Lacer Sa Derivados de mononitrato de isosorbida y su empleo como agentes vasodilatadores con tolerancia desminuida.
CZ20032339A3 (cs) * 2001-01-31 2004-09-15 Merck Patent Gmbh Farmaceutický prostředek obsahující parazolo [4,3-d]pyrimidiny a nitráty nebo thienopyrimidiny a nitráty
JP2005526092A (ja) * 2002-03-21 2005-09-02 ケイマン ケミカル カムパニー 緑内障および眼圧亢進を治療するためのプロスタグランジンＦ２α類縁体およびそれらの抗菌タンパク質との併用法
CN1863905A (zh) * 2003-09-08 2006-11-15 得克萨斯系统大学董事会 通过用前列腺素或前列腺素类似物补充培养基加强体外胚发育的方法以及组合物
ES2258365B1 (es) * 2003-10-03 2007-12-01 Lacer, S.A. Derivados de disulfuro, sulfuro, sulfoxido y sulfona de azucares ciclicos y sus usos.

Also Published As

Publication number Publication date
ATE472324T1 (de) 2010-07-15
ES2354317T3 (es) 2011-03-14
RU2009128968A (ru) 2011-02-10
NO20092763L (no) 2009-07-27
MX2009007040A (es) 2009-08-25
CN101600426B (zh) 2012-07-25
JP2010514734A (ja) 2010-05-06
WO2008080955A1 (en) 2008-07-10
RU2009128970A (ru) 2011-02-10
AU2007341218B2 (en) 2010-09-09
NO20092764L (no) 2009-07-27
CN101600425A (zh) 2009-12-09
JP2010514733A (ja) 2010-05-06
CA2674144A1 (en) 2008-07-10
CA2674550A1 (en) 2008-07-10
ES2324130A1 (es) 2009-07-30
AU2007341289A1 (en) 2008-07-10
ZA200903567B (en) 2010-08-25
ES2348314T3 (es) 2010-12-02
WO2008080939A1 (en) 2008-07-10
BRPI0720664A2 (pt) 2014-01-14
ZA200903566B (en) 2010-08-25
DE602007007523D1 (de) 2010-08-12
EP2114398B1 (en) 2010-06-30
ES2324130B1 (es) 2010-03-22
EP2114398A1 (en) 2009-11-11
IL198912A0 (en) 2010-02-17
US20080161389A1 (en) 2008-07-03
AU2007341218A1 (en) 2008-07-10
KR20090112673A (ko) 2009-10-28
MX2009007038A (es) 2009-08-25
AU2007341289B2 (en) 2010-08-26
UY30847A1 (es) 2008-05-31
KR20100100584A (ko) 2010-09-15
EP2124930A1 (en) 2009-12-02
IL198941A0 (en) 2010-02-17
CL2007003836A1 (es) 2008-07-11
BRPI0720663A2 (pt) 2014-01-14
EP2124930B1 (en) 2010-10-13
CL2007003837A1 (es) 2008-07-11
PL2124930T3 (pl) 2011-04-29
ATE484279T1 (de) 2010-10-15
DE602007009877D1 (de) 2010-11-25
CN101600426A (zh) 2009-12-09
EP1941876A1 (en) 2008-07-09
PL2114398T3 (pl) 2010-11-30

Similar Documents

Publication Publication Date Title
AR062397A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento de fibrosis
ECSP088902A (es) Derivados de pirazolo[3,4-d]-pirimidina utiles para tratar trastornos respiratorios
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
BRPI0611705A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de composto
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
WO2007046868A3 (en) Thiazolidine derivatives and their uses as therapeutic agents
ECSP109900A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
AR062390A1 (es) Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas
AR062401A1 (es) Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
WO2006125194A3 (en) Piperazine derivatives and their uses as therapeutic agents
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
AR048336A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
AR056369A1 (es) Compuestos derivados de quinazolina y composicion farmaceutica
CO6331429A2 (es) Derivados de 5-(4-metanosulfonil-fenil)-tiazol para el tratamiento de enfermedades inflamatorias agudas y cronicas
AR063819A1 (es) Pirrolo[1,2-a]imidazoldiona eficaz en el tratamiento de neurotoxicidad periferica inducida por agentes quimioterapeuticos. composiciones farmaceuticas y usos.
PA8789101A1 (es) Composición farmacéutica estable que comprende una sal de vinflunina hidrosoluble
AR064544A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes reductores de la hipertension ocular
UY30848A1 (es) Uso de derivados de mononitrato de dianhidrohexita?? como agentes reductores de la hipertension ocular

Legal Events

Date Code Title Description
FB Suspension of granting procedure